Comparison of efficacy and tolerability of tretinoin gel 0.05% with adapalene gel 0.1% in treating mild to moderate acne vulgaris

Ansar, Akram; Alirezaei, Pedram; Daneshyar, Sajjad; Sharafi, Bita; Torabian, Saadat

[Home ] [Archive]

[ فارسی ]

Main Menu

Home

Journal Information

Indexing Sources

Guide for Authors

Online Submission

Ethics

Articles archive

For Reviewers

Contact us

Basic and Clinical Biochemistry and Nutrition

DOAJ

CINAHL

EBSCO

IMEMR

ISC

Search in website

Receive site information

enamad

Volume 22, Issue 1 (Bimonthly 2018)

Feyz 2018, 22(1): 48-56

Back to browse issues page

Comparison of efficacy and tolerability of tretinoin gel 0.05% with adapalene gel 0.1% in treating mild to moderate acne vulgaris

Student Researcher Committee, Hamedan University of Medical Sciences, Hamedan, I. R. Iran. , s.danshyar72@yahoo.com

Abstract: (51963 Views)

Background: Acne vulgaris is an inflammatory skin disease. Topical retinoids with significant anti-inflammatory properties are used for treatment of acne. The common side effect of topical retinoids is local irritation. The aim of this study was to compare the efficacy and tolerability of tretinoin 0.05% and adapalene 0.1% in patients with mild to moderate acne vulgaris.
Materials and Methods: This randomized double-blind clinical trial was conducted on 50 patients referred to the dermatology clinic of Farshchian hospital in Hamadan city with mild to moderate facial acne. The patients were divided into two groups; the first group received tretinoin gel 0.05% and the second group adapalene gel 0.1%. The severity of acne was measured by Global Acne Grading System (GAGS) and tolerability was evaluated at the beginning of the trial, and 4 and 12 weeks thereafter in both groups.
Results: The mean GAGS score at the beginning of the study was 49.56 (SD=12.24) in the adapalene group and 47.76 (SD=11.34) in the tretinoin group (P=0.592). This score dropped to 35.00 (SD=11.13) in the adapalene and 25.28 (SD=8.17) in the tretinoin group in week 4 (P= 0.001). A further GAGS score decline was observed in week 12 (25.08±9.00 in the adapalene and 12.12±4.71 in the tretinoin group (P<0.001)). Regarding tolerability, there was no significant difference between the two groups at the end of weeks 4 and 12 (P=1.00 and P=0.747, respectively).
Conclusions: Adapalene 0.1% and tretinoin 0.05% are both effective and safe in treatment of mild to moderate acne vulgaris, although the tretinoin gel shows more efficacy in reducing the GAGS score. Both treatments are equally tolerated.

Keywords: Acne vulgaris, Tretinoin, Adapalene

Full-Text [PDF 338 kb] (8899 Downloads)

Type of Study: Research | Subject: medicine, paraclinic
Received: 2017/01/8 | Revised: 2018/03/18 | Accepted: 2017/11/11 | Published: 2018/01/10

References

1. Layton AM. A review on the treatment of acne vulgaris. Int J Clin Pract 2006; 60(1): 64-72.

2. Rad F, Yaghmaee R, Ghaderi EB. Comparison of the Therapeutic Efficacy of Azithromycin vs Tetracycline in Acne Vulgaris. Armaghane Danesh 2009; 14(2): 1-8. [in Persian]

3. Stern RS. Acne therapy. medication use and sources of care in office-based practice. Arch Dermatol 1996; 132(7): 776-80.

4. Silverberg NB, Weinberg JM. Rosacea and adult acne: a worldwide epidemic. Cutis 2001; 68(2): 85.

5. Smith RN, Braue A, Varigos GA, Mann NJ. The effect of a low glycemic load diet on acne vulgaris and the fatty acid composition of skin surface triglycerides. J Dermatological Sci 2008; 50(1): 41-52.

6. Purvis D, Robinson E, Merry S, Watson P. Acne, anxiety, depression and suicide in teenagers: A cross‐sectional survey of New Zealand secondary school students. J Paediatrics Child Health 2006; 42(12): 793-6.

7. Rapp DA, Brenes GA, Feldman SR, Fleischer AB Jr, Graham GF, Dailey M, et al. Anger and acne: implications for quality of life, patient satisfaction and clinical care. Br J Dermatol 2004; 151(1): 183-9.

8. Smith RN, Mann NJ, Braue A, Mäkeläinen H, Varigos GA. A low-glycemic-load diet improves symptoms in acne vulgaris patients: a randomized controlled trial. Am J Clin Nutr 2007; 86(1): 107-15.

9. Gawkrodger D, Ardern-Jones MR. Dermatology: an illustrated colour text: Elsevier Health Sciences; 2012.

10. Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet 2012; 379(9813): 361-72.

11. Thielitz A, Abdel‐Naser MB, Fluhr JW, Zouboulis CC, Gollnick H. Topical retinoids in acne–an evidence‐based overview. J Dtsch Dermatol Ges 2010; 8 Suppl 1: S15-23.

12. Eichenfield LF, Jarratt M, Schlessinger J, Kempers S, Manna V, Hwa J, et al. Adapalene 0.1% lotion in the treatment of acne vulgaris: results from two placebo-controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol 2010; 9(6): 639-46.

13. Jacyk WK, Mpofu P. Adapalene gel 0.1% for topical treatment of acne vulgaris in African patients. Cutis 2001; 68(4 Suppl): 48-54.

14. Stinco G, Bragadin G, Trotter D, Pillon B, Patrone P. Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. J European Academy Dermatol Venereol 2007; 21(3): 320-5.

15. Shapiro S, Heremans A, Mays DA, Martin AL, Hernandez-Medina M, Lanes S. Use of topicaltretinoin and the development of noncutaneous adverse events: Evidence from a systematic review of the literature. J Am Acad Dermatol 2011; 65(6): 1194-201.

16. Thiboutot DM, Shalita AR, Yamauchi PS, Dawson C, Kerrouche N, Arsonnaud S, et al. Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study. Arch Dermatol 2006; 142(5): 597-602.

17. Cunliffe WJ, Danby FW, Dunlap F, Gratton D, Greenspan A. Randomised, controlled trial of the efficacy and safety of adapalene gel 0.1% and tretinoin cream 0.05% in patients with acne vulgaris. Eur J Dermatol 2002; 12(4): 350-4.

18. Percy S. Safety and efficacy of adapalene gel 0.1% in acne vulgaris: Results of a post-marketing surveillance study. Indian J Dermatol Venereol Leprol 2003; 69(4): 277.

19. Kellum RE, Strangfeld K. Acne vulgaris. Studies in pathogenesis: Fatty acids of human surface triglycerides from patients with and without acne. J Invest Dermatol 1972; 58(5): 315-8.

20. Logan AC. Linoleic and linolenic acids and acne vulgaris. Br J Dermatol 2008; 158(1): 201-2.

21. Logan AC. Dietary fat, fiber, and acne vulgaris. J Am Acad Dermatol 2007; 57(6): 1092-3.

22. Zhu X, Tu P, Zhen J, Duan Y. Adapalene gel 0.1%: effective and well tolerated in the topical treatment of acne vulgaris in Chinese patients. Cutis 2001; 68(4 Suppl): 55-9.

23. Allen BS, Smith JG Jr. Various parameters for grading acne vulgaris. Arch Dermatol 1982; 118(1): 23-5.

24. Magin PJ, Adams J, Heading GS, Pond DC, Smith W. Complementary and alternative medicine therapies in acne, psoriasis, and atopic eczema: results of a qualitative study of patients' experiences and perceptions. J Altern Complement Med 2006; 12(5): 451-7.

25. Weiss JS, Thiboutot DM, Hwa J, Liu Y, Graeber M. Long-term safety and efficacy study of adapalene 0.3% gel. J Drugs Dermatol 2008; 7(6 Suppl): s24-8.

26. Cordain L, Lindeberg S, Hurtado M, Hill K, Eaton SB, Brand-Miller J. Acne vulgaris: a disease of Western civilization. Arch Dermatol 2002; 138(12): 1584-90.

27. Uhlenhake E, Yentzer BA, Feldman SR. Acne vulgaris and depression: a retrospective examination. J Cosmet Dermatol 2010; 9(1): 59-63.

28. Thiboutot DM, Weiss J, Bucko A, Eichenfield L, Jones T, Clark S, et al. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol 2007; 57(5): 791-9.

29. Phillips TJ. An update on the safety and efficacy of topical retinoids. Cutis 2005; 75(2 Suppl): 14-22.

30. Jain GK, Ahmed FJ. Adapalene pretreatment increases follicular penetration of clindamycin: In vitro and in vivo studies. Indian J Dermatol Venereol Leprol 2007; 73(5): 326.

31. Dréno B, Bettoli V, Ochsendorf F, Layton AM, Perez M, Dakovic R, et al. Efficacy and safety of clindamycin phosphate 1.2%/tretinoin 0.025% formulation for the treatment of acne vulgaris: pooled analysis of data from three randomised, double-blind, parallel-group, phase III studies. Eur J Dermatol 2014; 24(2): 201-9.

32. Tirado‐Sánchez A, Espíndola YS, Ponce‐Olivera RM, Bonifaz A. Efficacy and safety of adapalene gel 0.1% and 0.3% and tretinoin gel 0.05% for acne vulgaris: results of a single‐center, randomized, double‐blinded, placebo‐controlled clinical trial on Mexican patients (skin type III–IV). J Cosmetic Dermatol 2013; 12(2): 103-7.

33. Jain S. Topical tretinoin or adapalene in acne vulgaris: an overview. J Dermatolog Treat 2004; 15(4): 200-7.

34. Leyden JJ, Shalita A, Thiboutot D, Washenik K, Webster G. Topical retinoids in inflammatory acne: a retrospective, investigator-blinded, vehicle-controlled, photographic assessment. Clin Ther 2005; 27(2): 216-24.

35. Ioannides D, Rigopoulos D, Katsambas A. Topical adapalene gel 0• 1% vs. isotretinoin gel 0• 05% in the treatment of acne vulgaris: a randomized open‐label clinical trial. Br J Dermatol 2002; 147(3): 523-7.

36. Ahmed I, Sarwar M. Topical adapalene cream 0.1% v/s isotretinoin 0.05% in the treatment of acne vulgaris: a randomized open-label clinical trial. J Pakistan Association Dermatol 2016; 19(1): 23-5.

Send email to the article author

Add your comments about this article

Mendeley

Zotero

RefWorks

Ansar A, Alirezaei P, Daneshyar S, Sharafi B, Torabian S. Comparison of efficacy and tolerability of tretinoin gel 0.05% with adapalene gel 0.1% in treating mild to moderate acne vulgaris. Feyz 2018; 22 (1) :48-56
URL: http://feyz.kaums.ac.ir/article-1-3236-en.html

This open access journal is licensed under a Creative Commons Attribution-NonCommercial ۴.۰ International License. CC BY-NC ۴. Design and publishing by Kashan University of Medical Sciences.
Copyright ۲۰۲۳© Feyz Medical Sciences Journal. All rights reserved.

Volume 22, Issue 1 (Bimonthly 2018)

Back to browse issues page

Persian site map - English site map - Created in 0.05 seconds with 46 queries by YEKTAWEB 4645